Skip to main content
Fig. 2 | Cancer Nanotechnology

Fig. 2

From: Enhanced cancer immunotherapy through synergistic ferroptosis and immune checkpoint blockade using cell membrane-coated nanoparticles

Fig. 2

In vitro PD-L1 blockade and cytotoxicity analysis of PD-1@RSL3 NPs. a Flow cytometric analysis showed that PD-1 NVs binding with 4T1 cells significantly decreased after adding aPD-L1. b Quantitation of 4T1 cells bound to PD-1 NVs with or without aPD-L1 pretreatment. c, d In vivo biodistribution (c) and quantitative analysis (d) of Cy5.5-labeled Blank@RSL3 NPs and PD-1@RSL3 NPs in mice bearing 4T1 xenografts was evaluated by IVIS system. e Cytotoxicity analysis of PD-1@RSL3 NPs containing different RSL3 concentrations (ranging from 0 to 7.5 μM) against breast cancer cells in vitro. f Ferroptosis inhibitor Fer-1 reversed the tumor-killing induced by PD-1@RSL3 NPs in 4T1 cells (RSL3: 5 μM; Fer-1: 0.5 μM)

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us